The high cost of prescription drugs: causes and solutions

被引：95
作者：
Vincent Rajkumar, S. [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA
来源：
BLOOD CANCER JOURNAL | 2020年 / 10卷 / 06期
关键词：
D O I：
10.1038/s41408-020-0338-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 23 条
[1]  
Almashat S, 2017, PHARM RES COSTS MYTH
[2]  
Amin T, PATENT ABUSE IS DRIV
[3]  
Anderson G. F, ITS TIME LIMIT DRUG
[4]  
[Anonymous], 2019, Global oncology trends 2018
[5]  
[Anonymous], 2019, The Global Use of Medicine in 2019 and Outlook to 2023
[6]   Regulatory and clinical considerations for biosimilar oncology drugs [J].
Bennett, Charles L. ;
Chen, Brian ;
Hermanson, Terhi ;
Wyatt, Michael D. ;
Schulz, Richard M. ;
Georgantopoulos, Peter ;
Kessler, Samuel ;
Raisch, Dennis W. ;
Qureshi, Zaina P. ;
Lu, Z. Kevin ;
Love, Bryan L. ;
Noxon, Virginia ;
Bobolts, Laura ;
Armitage, Melissa ;
Bian, John ;
Ray, Paul ;
Ablin, Richard J. ;
Hrushesky, William J. ;
Macdougall, Iain C. ;
Sartor, Oliver ;
Armitage, James O. .
LANCET ONCOLOGY, 2014, 15 (13) :E594-E605
[7]  
Cohen M, POLICY OPTIONS INCRE, DOI DOI 10.1377/HBLOG20190103.333047
[8]   Innovation in the pharmaceutical industry: New estimates of R&D costs [J].
DiMasi, Joseph A. ;
Grabowski, Henry G. ;
Hansen, Ronald W. .
JOURNAL OF HEALTH ECONOMICS, 2016, 47 :20-33
[9]  
Erman M., MORE DRUGMAKERS HIKE
[10]  
Fein A. J, WE SHOULDNT GIVE BIO
123